Follow The Filings

ABEO Abeona Therapeutics Inc.

Health Care, filed as ABEONA THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $673K

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 0.09%

Who owns ABEO

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 0.09% Hold 108,865 $673K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ABEO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ABEO insider trades
  • None no insider bought on the open market
  • $330K sold by 2 insiders outside a trading plan
  • $547K sold by 3 insiders under 10b5-1 plans
  1. Mark Alvino Director
    Sale
    $88K 15,000 shares at $5.86 20% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  2. Leila Alland Director
    Sale
    $65K 11,000 shares at $5.92 6.3% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  3. Joseph Walter Vazzano CFO
    Planned sale
    $138K 25,646 shares at $5.39 4.7% of stake
    Traded Jun 9 Filed Jun 9
    ↗
  4. Mark Alvino Director
    Sale
    $35K 6,500 shares at $5.46 7.7% of stake
    Traded May 22 Filed May 22
    ↗
  5. Eric Crombez Director
    Planned sale
    $145K 26,143 shares at $5.53 41% of stake
    Traded May 15 Filed May 15
    ↗
  6. Vishwas Seshadri CEO
    Planned sale
    $131K 29,985 shares at $4.38 2.1% of stake
    Traded Mar 31 Filed Mar 31
    ↗
  7. Mark Alvino Director
    Sale
    $71K 13,500 shares at $5.23 22% of stake
    Traded Jan 21 Filed Jan 21
    ↗
  8. Vishwas Seshadri CEO
    Planned sale
    $133K 25,000 shares at $5.31 2.1% of stake
    Traded Dec 29, 2025 Filed Dec 29, 2025
    ↗
  9. Mark Alvino Director
    Sale
    $71K 15,000 shares at $4.74 19% of stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 29 sales to cover taxes, 13 stock grants, 1 gift, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13D — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B3 Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 7 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.5M — $5.82M
Gross profit * — — $4.29M
Gross margin * — — 73.7%
Net income -$54.19M -$63.73M $71.18M
Net margin * -1548.2% — 1223.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $55.74M $100.85M $204.91M
Total non-current assets * $8.26M $8.08M $14.66M
Total assets $64M $108.93M $219.57M
Total current liabilities $13.42M $16.59M $29.57M
Total non-current liabilities * $35.75M $48.31M $30.78M
Total equity $14.83M $44.03M $159.22M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$37.01M -$56.02M -$76.33M
Cash from investing $0.208M -$39.24M $105.03M
Cash from financing $37.06M $104.14M $26.04M
Net change in cash $0.256M $8.88M $54.74M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.